Zacks Investment Research
04 Nov 2026, 01:55 UTC · 13m ago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Impact · against what's priced in
Tarsus Pharmaceuticals (TARS) showed strong operational momentum with a significant EPS beat and 63.8% year-over-year revenue growth. The reversal from a previous earnings miss suggests a potential improvement in the company's trajectory and operational efficiency.
- TARS+0.50
No priced-in read yet
- In context
TARS reported a smaller than expected adjusted loss of $0.78 per share against a $1.43 estimate and revenues of $194.57 million, beating consensus by 3.06%.
Read from the article alone
